文献速递瓣膜病与结构性心脏病

外科主动脉生物瓣植入后的长期结局

Long-Term Outcomes Following Surgical Aortic Bioprosthesis Implantation.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

该研究纳入2002至2004年连续672例接受外科主动脉瓣置换术并植入生物瓣的患者,前瞻性收集随访数据。中位随访10年时64.3%患者死亡,临床相关结构性瓣膜退变发生率为6.6%,亚临床结构性瓣膜退变为30.1%。

要点

  • 中位随访10年,432例(64.3%)患者死亡,高龄和合并症是主要死亡风险因素。
  • 临床相关结构性瓣膜退变发生率为6.6%,亚临床结构性瓣膜退变为30.1%。
  • 体重指数较高和使用特定主动脉生物瓣与临床相关结构性瓣膜退变独立相关。

核心结论

  • 老年外科主动脉生物瓣植入者10年死亡率较高,主要由高龄和合并症决定。
  • 临床相关结构性瓣膜退变不常见,但近三分之一患者存在亚临床结构性瓣膜退变。

研究设计与样本

  • 研究纳入2002至2004年连续672例接受外科主动脉瓣置换术并植入生物瓣的患者(平均年龄72±8岁,61.5%男性),前瞻性收集基线与随访数据。
  • 出院时存活624例获得基线术后超声心动图数据,10年时209例(占风险患者87%)获得超声心动图数据。

主要发现

  • 中位随访10年(四分位距5至13年),432例(64.3%)死亡。
  • 高龄、左心室功能不全、心房颤动、慢性阻塞性肺疾病、较高体重指数和糖尿病与死亡风险增加相关(P均<0.05)。
  • 临床相关结构性瓣膜退变发生率为6.6%,亚临床结构性瓣膜退变为30.1%。
  • 较高体重指数和使用特定主动脉生物瓣与临床相关结构性瓣膜退变独立相关(P均<0.05),其中83%患者接受了主动脉瓣再干预(44%为瓣中瓣经导管主动脉瓣置换术)。

关键数值与推荐

  • 亚临床结构性瓣膜退变定义为平均跨瓣压差增加>10 mm Hg且瓣口面积减少>0.3 cm2,和/或新发轻度或中度主动脉瓣反流。
  • 临床相关结构性瓣膜退变定义为平均跨瓣压差增加>20 mm Hg且瓣口面积减少>0.6 cm2,和/或新发中度至重度主动脉瓣反流。

临床怎么用

  • 对于老年外科主动脉生物瓣植入患者,应重视高龄和合并症对长期生存的影响。
  • 术后长期随访中需关注结构性瓣膜退变,尤其亚临床退变发生率达30.1%。
  • 体重指数较高和使用特定生物瓣的患者应加强结构性瓣膜退变监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few data exist on long-term outcomes and structural valve degeneration (SVD) in consecutive unselected patients undergoing surgical aortic valve replacement (SAVR). OBJECTIVES: The goal of this study was to determine the long-term outcomes of a contemporary cohort of consecutive unselected SAVR recipients with a focus on evaluating clinical outcomes and SVD based on echocardiographic criteria. METHODS: A total of 672 consecutive patients (mean age: 72 ± 8 years; 61.5% male) undergoing SAVR with a bioprosthesis between 2002 and 2004 were included. Baseline and follow-up data were prospectively collected in a dedicated database. Baseline post-operative echocardiographic data were obtained in the 624 patients alive at hospital discharge and in 209 patients at 10 years (87% of the patients at risk). SVD was defined as subclinical (increase >10 mm Hg in mean transvalvular gradient + decrease >0.3 cm2 in valve area and/or new-onset mild or moderate aortic regurgitation) and clinically relevant (increase >20 mm Hg in mean transvalvular gradient + decrease >0.6 cm2 in valve area and/or new-onset moderate-to-severe aortic regurgitation). RESULTS: At a median follow-up of 10 years (interquartile range: 5 to 13 years), 432 patients (64.3%) had died. Older age, left ventricular dysfunction, atrial fibrillation, chronic obstructive pulmonary disease, greater body mass index, and diabetes mellitus were associated with an increased mortality risk (p < 0.05 for all). Clinically relevant SVD occurred in 6.6% of patients; 30.1% of patients had subclinical SVD. A greater body mass index and the use of a specific aortic bioprosthesis were independently associated with clinically relevant SVD (p < 0.05 for both), and 83% of these patients underwent aortic valve reintervention (valve-in-valve transcatheter aortic valve replacement in 44% of them). CONCLUSIONS: The 10-year mortality rate in elderly SAVR recipients of a bioprosthetic valve was considerable, chiefly determined by their older age and the presence of comorbidities. Clinically relevant SVD was infrequent, but close to one third of the population exhibited subclinical SVD. These results provide contemporary data on long-term clinical outcomes and SVD post-SAVR, and they should be taken into consideration when evaluating late clinical outcomes and valve durability after transcatheter aortic valve replacement.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Gabella T, Voisine P, Dagenais F, et al. Long-Term Outcomes Following Surgical Aortic Bioprosthesis Implantation. J Am Coll Cardiol. 2018. PMID: 29598859. doi:10.1016/j.jacc.2018.01.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。